The safety of avasimibe and ability to re-sensitise TKI resistant BCR::ABL1+ cell lines to TKI treatment, indicates that targeting cholesterol storage may serve as an effective combination treatment strategy in TKI resistant CML patients. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.